Regulatory changes relating to food labeling, taxation, social insurance systems and other matters
First written in FY2016. 3 of 5 entries say "Restated". Latest entry: FY2025.
2 other companies' latest entry also says "Restated".
- FY2025RestatedAnnual report
「Our group’s business is subject to legal regulations including the Food Sanitation Act, the Food Labelling Act and the Act against Unjustifiable Premiums and Misleading Representations (the Premiums and Representations Act).」
The company continues to identify risks of business constraints and administrative sanctions arising from food labelling and sanitation, representations of premiums, taxation and legislative changes. - FY2020RestatedAnnual report
「Our group’s business is subject to legal regulations including the Food Sanitation Act, the Food Labelling Act and the Act against Unjustifiable Premiums and Misleading Representations (the Premiums and Representations Act).」
The company continues to identify risks of business constraints and administrative sanctions arising from food labelling and sanitation, representations of premiums, taxation and legislative changes. - FY2019RestatedAnnual report
「Our group makes compliance with laws and regulations its highest priority and is working to establish the necessary framework, including by formulating rules and manuals. However, if a violation of these regulations occurs and an administrative sanction or other penalty is imposed, this could damage our reputation and affect our group’s performance and financial condition.」
The company describes a framework that makes compliance its highest priority, while continuing to identify risks of business constraints and administrative sanctions arising from food labelling, taxation and legislative changes. - FY2017MaterialisedAnnual report
「The company and 3 of its employees were referred to prosecutors on suspicion of violating the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (the “Pharmaceuticals and Medical Devices Act”). The company and 1 employee each received summary orders imposing a fine of ¥500,000, while 2 employees were not prosecuted.」
The company states that the compliance risk previously disclosed as a future risk arising from changes in laws and tax systems actually materialised in the form of referrals to prosecutors on suspicion of violating the Pharmaceuticals and Medical Devices Act and summary orders imposing fines. - FY2016First statedAnnual report
「In addition, the scope of social insurance premium coverage for short-time workers was scheduled to expand from October 2016. The resulting increase in expenses could affect our group’s performance and financial condition.」
The company identifies the possibility of increased costs and business constraints resulting from the Food Sanitation Act, the JAS Act, the Act against Unjustifiable Premiums and Misleading Representations, consumption tax rates and reduced tax rates, and the expanded application of social insurance to short-time workers.